Evaluation of Quality of Care - Multi-disciplinary Risk Assessment and Management Programme for Patients With Hypertension, HA (QoC RAMP-HT)
Launched by THE UNIVERSITY OF HONG KONG · Aug 16, 2014
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • HT
- • aged \<80
- • Suboptimal BP control (average systolic blood pressure (SBP) ≥ 140mmHg or average diastolic blood pressure (DBP) ≥ 90mmHg)
- Exclusion Criteria:
- • Patients will be excluded if they are unable to understand or communicate in Chinese language, or refuse to give consent.
- • Patients will be excluded if they had prior history of diabetes and existing cardiovascular diseases
Trial Officials
Cindy L.K. Lam, MD
Study Chair
Department of Family Medicine and Primary Care, Faculty of Medicine, The University of Hong Kong
Esther Y.T. Yu, MBBS
Principal Investigator
Department of Family Medicine and Primary Care, Faculty of Medicine, The University of Hong Kong
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong Island, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
